BILTHOVEN, The Netherlands, January 22 /PRNewswire/ -- Progentix
Orthobiology B.V. announced today the closure of its Series A financing
Round. The round was led by BioGeneration Ventures.
Progentix Orthobiology B.V. was established in 2007 and develops a
unique suite of osteoinductive material products for clinical application
in bone regenerative surgery. Progentix bone graft material is based on
surface structured ceramic biomaterial scaffolds that have the ability to
attract growth factors and stems cells after implantation, which results in
the induction of bone growth. These materials are not only superior to
currently available synthetic ceramic bone grafts, but based on their bone
healing and regeneration potential also directly compete with the gold
standard of autologous bone, and the growth factors that are being used
today and those under development. The Series A financing round will
support further technology validation and the generation of clinical proof
of principle.
Dr. Joost de Bruijn, CEO of Progentix Orthobiology said: "We are
extremely pleased with the support of BioGeneration Ventures. This
financing round will allow us to continue building value and lay the
groundwork for the launch of our first products in the near future."
"We strongly believe in the high quality of the Progentix Orthobiology
technology," says Edward van Wezel M.Sc., managing partner at BioGeneration
Ventures BV. "This novel technology platform will address a real medical
need in the area of bone grafts. The scientific team has an excellent track
record in the development of biomaterials and tissue engineering." Dr.
Clemens van Blitterswijk, professor in Tissue Regeneration at the
University of Twente and former CEO of IsoTis N.V., and Edward van Wezel
will join the board of directors of Progentix Orthobiology.
About Biogeneration Ventures BV
BioGeneration Ventures invests in Dutch Life Sciences companies. The
team of BioGeneration is specialized in the evaluation of new technologies
and in the management of start-up companies. BioGeneration Ventures was
co-founded by the Netherlands Genomics Initiative (NGI), NWO, the holding
of the University of Leiden, and ABN-AMRO Capital. BioGeneration closely
cooperates with Forbion Capital Partners (http://www.forbion.com).
Contact:
Progentix Orthobiology B.V.
Prof. Dr. Joost de Bruijn
T: +31-30-2295234
E: info@progentix.com
W: http://www.progentix.com
BioGeneration Ventures B.V.
Edward van Wezel
T: +31-35-6993011
E: info@biogenerationventures.com
W: http://www.biogenerationventures.com
SOURCE Progentix Orthobiology
 back to top
CONTACT:
Contact: Progentix Orthobiology B.V., Prof.
Dr. Joost de Bruijn, T: +31-30-2295234, E: info@progentix.com;
BioGeneration Ventures B.V., Edward van Wezel, T: +31-35-6993011,
E: info@biogenerationventures.com
|
